Scientists have reported progress in developing a blood test that could identify individuals at higher risk of developing lung cancer, a disease for which screening has historically lagged behind other cancers. Unlike prostate, colon and breast cancers, lung cancer screening has not been very successful, largely because it focuses primarily on smoking history, yet many people who develop the disease do not have a history of smoking, according to a press release.
The new blood test aims to flag individuals at elevated risk, potentially enabling earlier detection and treatment. As it becomes easier to detect lung cancer earlier, new treatment modalities, such as those being developed by Calidi Biotherapeutics Inc. (NYSE American: CLDI) and other therapies under development, could benefit from improved screening.
The announcement comes from BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @IBN that covers developments in the biotechnology and life sciences sectors. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
The implications of this research are significant. Lung cancer remains the leading cause of cancer death worldwide, and late-stage diagnosis contributes to poor survival rates. A blood test that can identify high-risk individuals, regardless of smoking history, could revolutionize screening protocols. Current guidelines recommend low-dose CT scans only for heavy smokers, leaving many non-smokers with lung cancer undiagnosed until symptoms appear.
If validated, the test could lead to earlier intervention, potentially improving outcomes and reducing mortality. The development also underscores the growing role of liquid biopsies in cancer detection, offering a non-invasive alternative to traditional imaging and tissue biopsies.
For more information, visit BioMedWire and review their full terms of use and disclaimers at https://www.BioMedWire.com/Disclaimer.
